Unilateral Lung Infiltrate: A Rare Form of Presentation of Primary Pulmonary Lymphoma

Torralbo, J.A. Delgado; Gómez, L; Varilla, J.M. Sánchez

doi:10.1016/j.arbr.2017.12.002

Cited by 1 publication

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Primary pulmonary lymphoma (PPL) is defined as a clonal lymphoid proliferation affecting one or both lungs in patients with no detectable extrapulmonary involvement or bone marrow disease at the time of diagnosis and during the subsequent 3 months (1). This disease is a rare entity that accounts for 1% of malignant lymphomas (2) and 3.6% of extranodal lymphomas worldwide (3). The rarity of PPL may be attributed to the relatively low levels of lymphoid tissue in pulmonary tissue compared with the levels at other sites (4).…”

Section: Introductionmentioning

confidence: 99%

Diagnostic and prognostic factors for patients with primary pulmonary non‑Hodgkin's lymphoma: A 16‑year single‑center retrospective study

et al. 2019

View full text Add to dashboard Cite

Primary pulmonary non-Hodgkin's lymphoma (PP-NHL) is a rare entity with non-specific symptoms and radiographic findings, as well as a difficult preoperative diagnosis. A limited number of studies have described PP-NHL in Chinese patients. The goal of the present study was to improve early diagnosis by examining prognostic factors in patients with PP-NHL. Therefore, a total of 29 patients with PP-NHL were included in the study between January 2001 and June 2017, including 14 with aggressive-type and 15 with indolent-type lymphomas (10 male, 19 female; median age, 50.3 years; range, 19-87 years). Pulmonary nodules and masses (55.2%) were the most common radiographic features. The diagnostic yield was 80% (12/15) by endobronchial biopsy or transbronchial lung biopsy and 100% by computed tomography (CT)-guided percutaneous needle lung biopsy (11/11) or surgery (8/8). Elevated lactate dehydrogenase levels and systemic symptoms were observed considerably more often in patients with aggressive disease than in those with indolent disease. The 1-, 3-and 5-year overall survival (OS) rates were 42, 32, and 21%, respectively, for all patients, 72, 57 and 43%, respectively, for patients with indolent lymphomas, and 13, 6 and 0%, respectively, for patients with aggressive lymphomas. The median OS rate for all patients was 12.0 months; however, the OS rate for patients with aggressive lymphomas was significantly shorter compared with those with indolent lymphomas (7.1 months vs. 16.6 months; P=0.002). Aggressive vs. indolent lymphoma status was indicated to be an independent prognostic factor for poor 5-year OS rate (hazard ratio, 5.98; P=0.014). In conclusion, bronchoscopic and CT-guided percutaneous needle lung biopsies were the most useful and least invasive procedures for diagnosing PP-NHL. Furthermore, aggressive PP-NHL was highly associated with poor 5-year OS rate and a poor prognosis.

show abstract

Section: Introductionmentioning

confidence: 99%